Organigram targets $10 million in cost savings
Organigram Global (NASDAQ:OGI) completed its integration of Sanity Group GmbH while targeting up to $10 million in annualized cost savings.
Todas as matérias desta seção, das mais recentes às mais antigas — página 25 de 371.
Organigram Global (NASDAQ:OGI) completed its integration of Sanity Group GmbH while targeting up to $10 million in annualized cost savings.
TSMC (NYSE:TSM) has entered into discussions regarding potential collaboration on Elon Musk's Terafab project while maintaining that it must operate any semiconductor plant in an alliance.
Taiwanese President Lai Ching-te called on Micron Technology (NASDAQ:MU) and its workers to negotiate sincerely following union authorization for potential strike action over a bonus scheme dispute.
Brent Crude futures fell 1.7% to $104.30 a barrel on Thursday as potential US sanction relief offset escalating supply risks in the Strait of Hormuz.
Gibraltar Industries (NASDAQ:ROCK) has agreed to sell its infrastructure business, D.S. Brown, to Saint-Gobain for $208 million in cash.
Taiwan Semiconductor Manufacturing Company (NYSE:TSM) reported a record third-quarter net profit of NT$763.06 billion ($23.55 billion), driven by sustained global demand for artificial intelligence chips.
Winmark Corporation (NASDAQ:WINA) reported net income of $11.8 million, or $3.21 per diluted share, for the quarter ended September 26, 2026.
Apple (NASDAQ:AAPL) has asked a federal judge in San Diego to overturn a $5.7 billion patent verdict won by Taction Technology over haptic feedback technology used in Apple’s iPhones and Apple Watches.
AmpliTech Group (NASDAQ:AMPG) announced that it secured over $17 million in customer purchase orders during the quarter ended September 30, 2026.
Netflix (NASDAQ:NFLX) has officially announced a workforce reduction of approximately 1,000 employees, representing about 6% of its global workforce.
Fluence Energy (NASDAQ:FLNC) signed an agreement with Vattenfall to deliver the planned Brunsbüttel battery storage facility and provide long-term service support.
The Progressive Corporation (NYSE:PGR) reported third-quarter 2026 financial results, with earnings per share of $4.37 compared with analyst expectations of $4.42.
Sarepta Therapeutics (NASDAQ:SRPT) presented new preclinical findings from its SRP-1003 program at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS).
Viking Therapeutics (NASDAQ:VKTX) announced the start of its SUNRISE Phase 3 clinical program for oral VK2735, an investigational therapy being developed for obesity management.
Alpha Compute (NASDAQ:ALP) announced that it entered into a binding GPU compute services agreement on October 9, 2026, for its first contracted U.S. GPU cluster.
Parabilis Medicines (NASDAQ:PBLS) announced the initiation of a new dose-ranging cohort for zolucatetide in adults with familial adenomatous polyposis, a hereditary condition associated with the development of precancerous polyps.
Takeda Pharmaceutical (NYSE:TAK) presented new data from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating TAK-881 Immune Globulin Subcutaneous (Human), 20% Solution combined with recombinant human hyaluronidase.
Entrada Therapeutics (NASDAQ:TRDA) announced that an independent monitoring committee has recommended initiating Cohort 3 of its Phase 1/2 ELEVATE-44-201 clinical study.
Fusion Fuel (NASDAQ:HTOO) reported first-half 2026 financial results and provided its outlook for the remainder of the year.
Morgan Stanley (NYSE:MS) reported third-quarter 2026 financial results, beating analyst expectations on both revenue and earnings.
State Street Corporation (NYSE:STT) reported third-quarter 2026 financial results, with adjusted earnings per share of $3.69, beating analyst expectations of $3.67.
Entrada Therapeutics (NASDAQ:TRDA) announced initial results from the first cohort of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne muscular dystrophy.
Eton Pharmaceuticals (NASDAQ:ETON) announced exclusive U.S. licensing and supply agreements with Aquestive Therapeutics (NASDAQ:AQST) for LIBERVANT, a seizure-cluster treatment.
Sono-Tek (NASDAQ:SOTK) reported fiscal first-half 2027 financial results, with revenue increasing 6% year over year to $10.893 million.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade